CIK 0001637715 · <br>Emerging growth company
OnKure Therapeutics, Inc.
Sign in to watch- Ticker
- OKUR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472309515
- Phone
- (720) 307-2892
- Business address
- 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301
- Former names
- Reneo Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,157
- in 2 filings
Net −$1,157. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-07 | Manke Isaac Director | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2026-08-07 | Manke Isaac Director | Returned to the company · Stock Option (right to buy) | −15,300 | 0 | ||
| 2026-08-07 | Manke Isaac Director | Grant or award · Stock Option (right to buy) | +15,300 | 15,300 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Returned to the company · Employee Stock Option (right to buy) | −2,359 | 0 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +2,359 | 2,359 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Returned to the company · Employee Stock Option (right to buy) | −1,485 | 0 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +1,485 | 1,485 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Returned to the company · Employee Stock Option (right to buy) | −8,449 | 0 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +8,449 | 8,449 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Returned to the company · Employee Stock Option (right to buy) | −16,898 | 0 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +16,898 | 16,898 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Returned to the company · Employee Stock Option (right to buy) | −542,232 | 0 | ||
| 2026-08-07 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +542,232 | 542,232 | ||
| 2026-08-07 | Ratcliffe Liam Director | Grant or award · Stock Option (right to buy) | +22,350 | 22,350 | ||
| 2026-08-07 | GREY MICHAEL G Director | Grant or award · Stock Option (right to buy) | +22,350 | 22,350 | ||
| 2026-08-07 | Mathers Edward T Director | Grant or award · Stock Option (right to buy) | +22,350 | 22,350 | ||
| 2026-06-22 | Leverone Jason A. Chief Financial Officer | Sale | −303 | $4.40 | $1K | 18,802 |
| 2026-06-22 | Saccomano Nicholas A President and CEO | Sale | −86 | $4.40 | $378 | 11,247 |
| 2026-06-04 | Phillips Andrew John Director | Grant or award · Stock Option (right to buy) | +7,650 | 7,650 |
Page 2 of 8 · 154 trades